New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Scribe Therapeutics Inc.

SCTX

Healthcare Biotechnology

Scribe Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $51.2 million.

12.07 1.15 −8.70%

After hours trading: 12.00, down 0.58%, last trade Fri 7:39pm Eastern.

Market cap
$250.4M
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
n/a
ROIC
—
Net debt / EBITDA
—
Payout ratio
—

Scribe Therapeutics Inc. (SCTX) Return on invested capital

Alert me on Return on invested capital

Return on invested capital, annual

No history to chart for SCTX yet.

Annual newest first

Period Return on invested capital Change (points)

Return on invested capital against peers

Company Return on invested capital
QTTB Q32 Bio Inc. compare 0.00%
EIKN Eikon Therapeutics, Inc. compare 0.00%
PRLD Prelude Therapeutics Incorporated compare 0.00%
OCGN Ocugen, Inc. compare 0.00%
CAMP CAMP4 Therapeutics Corporation compare 0.00%
AUTL Autolus Therapeutics PLC Sponsored ADR compare 0.00%
SABS SAB Biotherapeutics, Inc. compare −48.4%
IPSC Century Therapeutics, Inc. compare −71.5%
SCTX Scribe Therapeutics Inc. —
Biotechnology industry median 0.00%
Healthcare sector median 0.00%
Market median 0.06%

What Return on invested capital is

Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.

TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)

The full definition of Return on invested capital →

More on SCTX